BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences

From Startup Brainstorm Cell Therapeutics

Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2375846

Highlights Preclinical Research and Continued Progress of NurOwn® Platform in ALS Pivotal Trial
NEW YORK and PETACH TIKVAH, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that it will highlight progress with ongoing preclinical research and their proprietary NurOwn® technology platform at November clinical and investor conferences.
Clinical Conferences
Neuroscience 2018 Conference, San Diego, CA
Date:
November 7, 2018
Time:
1:00-2:00pm
Location:
SDCC Halls B-H
Session 761:
Neurotoxicity, Inflammation, Neuroprotection: Neuroprotective Mechanisms: Preclinical (761.05 / MM14)
Presenter:
Ralph Kern, M.D., MHSc, COO & CMO, Brainstorm Cell Therapeutics Inc.
Poster:
“Development of MSC-NTF Cell Exosomes for Neurodegenerative Diseases.”
More Information: Abstract of the poster is available here.
Investor Conferences
Inv€$tival Showcase, London, England— Chaim Lebovits, President & CEO will provide a corporate update presentation during the Jeffries-partnered Biotech & Money Inv€$tival Showcase.                   
Date:
November 13, 2018
Time:               
11:00am
Location:
ADELPHI 2
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform through an exclusive, worldwide licensing agreement. NurOwn® has received Fast Track designation from the U.S. Food and Drug Administration (U.S. FDA) in ALS and orphan status by the U.S. FDA and the European Medicines Agency (EMA). BrainStorm is currently enrolling a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of NurOwn® at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of NurOwn® in ALS. For more information, visit BrainStorm’s website at www.brainstorm-cell.com.
Safe-Harbor Statements
Statements in this announcement other than historical data and information constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm’s limited operating history, history of losses; minimal working capital, dependence on its license to Ramot’s technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
CONTACT
Media:Joseph PetrozielloBrainStorm Cell TherapeuticsPhone: +1.215.485.6797Email:  JP@brainstorm-cell.com
Investors:Marcy Beth NanusSolebury TroutPhone: +1.646.378.2927Email: MNanus@troutgroup.com

BrainStorm Cell Therapeutics Inc.

Please visit their site for more information: Brainstorm Cell Therapeutics.com

All,Biotechnology,Healthcare News,Startup News
2018-11-08 06:08:25